Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician

Miehlke, Stephan, Barreiro-de Acosta, Manuel, Bouma, Gerd, Carpio, Daniel, Magro, Fernando, Moreels, Tom and Probert, Chris ORCID: 0000-0003-4550-0239
(2018) Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33 (9). pp. 1574-1581.

[img] Text
Budesonide review (J Gast Hep) (revised) (20.2.18).docx - Author Accepted Manuscript

Download (182kB)


Oral budesonide is a second-generation steroid that allows local, selective treatment of the gastrointestinal tract and the liver, minimizing systemic exposure. The results of randomized trials comparing budesonide versus placebo or active comparators have led to expert recommendations that budesonide be used to treat mild or moderate active ileocecal Crohn's disease, microscopic colitis (including both collagenous and lymphocytic colitis), ulcerative colitis, and non-cirrhotic autoimmune hepatitis. The mechanism of budesonide action obviates the need for dose tapering due to safety reasons after induction therapy. Where low-dose budesonide is used to maintain remission, usually in microscopic colitis, it does not appear to have adverse safety implications other than slight reductions in cortisol levels on rare occasions. As a gut-selective and liver-selective corticosteroid, budesonide offers an appealing alternative to conventional systemic glucocorticoids in diseases of these organs.

Item Type: Article
Uncontrolled Keywords: autoimmune liver disease, Budenofalk, budesonide, Cortiment, Crohn's disease, Entocort, inflammatory bowel disease, microscopic colitis, tapering, ulcerative colitis
Depositing User: Symplectic Admin
Date Deposited: 30 Apr 2018 08:15
Last Modified: 19 Jan 2023 06:35
DOI: 10.1111/jgh.14151
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3020685